Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.
Results from the Rheumatoid Arthritis Responder Dream Challenge did not support the use of common SNP data to improve treatment response prediction models.
Firalis is developing an assay based on HTG's EdgeSeq platform to identify rheumatoid arthritis patients likely to respond to anti-TNF-alpha therapies.
IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.
The approach can increase CpG coverage about 18-fold by inferring from existing data to predict methylation of sites outside those covered on the arrays themselves.
